Relmada Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -23,008 | -18,818 | -22,987 | |
EBIT | -37,637 | -45,975 | ||
Net Income | -18,657 | -21,725 | -17,768 | -21,828 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -8,799 | -16,656 | -13,263 | -13,036 |
Cash | 3,857 | 1,483 | 2,086 | 1,335 |
Basic Shares | 30,174 | 30,174 | 30,174 | 30,132 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1 | |||
EBITDA | 4,910 | -157,043 | -125,750 | |
EBIT | -98,791 | -157,045 | -125,751 | |
Net Income | -79,979 | -98,791 | -157,043 | -125,751 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -39,047 | |||
Free Cash Flow | -51,755 | -51,659 | -103,801 | -91,873 |
Cash | 3,857 | 4,091 | 5,395 | 44,443 |
Basic Shares | 30,174 | 30,099 | 29,628 | 17,552 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.62 |
2024-09-30 | -$0.72 |
2024-06-30 | -$0.59 |
2024-03-31 | -$0.72 |
